[vc_row njt-role-user-roles=”administrator,armember”][vc_column][vc_column_text]
To test the effectiveness of its molecule against Covid-19, the Pasteur Institute of Lille is launching a clinical trial financed by LVMH for 5 million euros.
The luxury goods giant LVMH is going to donate 5 million euros to the Pasteur Institute of Lille to finance France’s research effort in the fight against the coronavirus (Covid-19). The objective? The upcoming launch of a clinical trial to “verify the efficacy” of a molecule tested in vitro against Covid-19.
A project “made possible” by this donation. “Researchers at the Pasteur Institute of Lille have recently identified a molecule that is particularly effective – in vitro – against the SARS-Cov-2 virus“. says in a press release the Institute, a private research foundation recognized as being of public utility.
To “continue their work” and “confirm the effectiveness of this treatment, researchers must now proceed as soon as possible with clinical trials“, the press release states.
The planned “large-scale” clinical trial will be financed by an “exceptional contribution” from the luxury group LVMH, which “came into contact “with the establishment “as soon as the first results of this work were announced“.
“It is thanks to the mobilization of donors and companies that the Pasteur Institute of Lille has been able to engage in this fight against Covid-19“, emphasizes Professor Xavier Nassif, Director General of the Pasteur Institute of Lille cited in the press release.
The molecule presented by the management of the institute as “very promising” was identified by Apteeus, a strat-up hosted by the Institute which is specialized in the repositioning of drugs and which has screened 2,000 of them, already donated to humans.
According to the indications given at the end of September to the AFP by Xavier Nassif, this molecule, which seems to be very powerful against the virus, “will be without equivalent if it is shown to work in vivo“.
Belonging to the category of antivirals, it is used in a drug that is currently available “only in certain European countries“. according to him.
For his part, Bernard Arnault, also quoted in the press release, declared : “It is vital that this research can continue and it is with this aim in mind that I have decided to provide support for this crucial phase of clinical trials“.
The Pasteur Institute of Lille invests 17 million euros each year in research thanks to donations, legacies and corporate sponsorship.
Read also > STOCK MARKET: LVMH STABLE, DESPITE THE LAWSUIT AGAINST TIFFANY
Featured photo: © Press[/vc_column_text][/vc_column][/vc_row]
